Adjuvant treatment with catechol-O-methyltransferase inhibitors inferior to monoamine oxidase type B inhibitors or dopamine agonists in patients with Parkinson disease uncontrolled by levodopa therapy
1. No significant improvement in quality of life was observed between treatment with dopamine agonists compared to dopamine reuptake inhibitors ...